BioSpace News Archive

People with spinal muscular atrophy are relying on recently approved condition-specific treatments and are hopeful the treatment pipeline can continue to have a positive impact, according to a recent survey conducted by Health Union, the leader in social health.

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces its sponsorship of the Fall Clinical Dermatology Conference, being held October 20-23 in Las Vegas.

American Molecular Laboratories (AML), a state-of-the-art molecular diagnostic and biotech development company based in Chicago, Illinois, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.

AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization, announced the appointment of Derek Hennecke and Marshall Crew as independent members of its board of directors.

OpenBench, Inc. announced that it has entered into a success-driven collaboration with Volastra Therapeutics, Inc., an oncology company focused on exploiting chromosomal instability to treat cancer, in which OpenBench will discover novel, potent small molecule antagonists to enrich Volastra’s early discovery efforts against an undisclosed cancer target.

According to Nova one advisor, the global AI In Oncology market size is expected to hit around USD 9.45 billion by 2030 from valued at USD 578.5 million in 2021 and growing at a CAGR of 35.10 % from 2022 to 2030.

According to Nova one advisor, the global Artificial Intelligence (AI) in Remote Patient Monitoring market size was valued at USD 1,122.16 million in 2022 and is predicted to hit USD 4,527.32 million by 2030 with a registered CAGR of 26.72% during the forecast period 2022 to 2030.

The global Legionella Testing market size was estimated at USD 300 million in 2022 and is expected to surpass around USD 510 million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 10.2% during the forecast period 2022 to 2030.

The global Artificial Intelligence In Diagnostics market size was estimated at USD 580.3 million in 2021 and is expected to surpass around USD 5.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 26.7% during the forecast period 2022 to 2030.

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming investor conferences.